BIOLASE Responds to Patent Action ezlase(R) Sales Move Forward Worldwide
IRVINE, CA, Apr 30, 2012 (MARKETWIRE via COMTEX) --
BIOLASE Technology, Inc.
BLTI
-1.50%
, the World's leading dental
laser company, today announced that West Jordan, UT-based CAO Group,
Inc. has filed a lawsuit against BIOLASE in the United States
District Court for the District of Utah, Central Division, alleging
patent infringement involving BIOLASE's ezlase(R) diode laser. The
only claimed novelty of the single asserted patent pertains to how
excessive fiber is stored, and does not relate to the actual advanced
design, features and functions of the ezlase. The lawsuit was filed
by the plaintiff without first contacting BIOLASE, and as of today,
the plaintiff has not served the complaint on BIOLASE.
Federico Pignatelli, Chairman and Chief Executive Officer of BIOLASE,
stated, "With close to 300 issued and pending patents, we are very
confident in the breadth of our intellectual property portfolio, and
in the strength of our laser technology. We are quite intrigued by
this attack on BIOLASE, and we will fully and vigorously defend
BIOLASE against any allegations levied by CAO which are without
merit."
BIOLASE's ezlase is perhaps the most versatile diode laser available
on the market today, and with more than 5,000 units sold, ezlase has
become the trusted choice of dentists and hygienists around the
world. In early 2007, BIOLASE received 510(k) clearance from the U.S.
Food and Drug Administration (FDA) to market ezlase. In December
2008, the Company received an additional FDA 510(k) clearance for
tooth whitening, and in April 2009, the Company received a third FDA
510(k) clearance for pain relief and therapy with application in
sports medicine, orthopedics, physical therapy and chiropractic
medicine.
Pignatelli continued, "BIOLASE is an early pioneer in the field and
this year proudly celebrates its 25-year anniversary. Its
intellectual property portfolio is the cornerstone of laser
technology in dentistry. Indeed, some of our competitors license our
IP in their own laser products. CAO, an upstart newcomer to our
esteemed industry, contends that the ezlase, which has been on the
market for more than five years, infringes on what appears to be a
narrow patent that received minimal scrutiny from the patent office.
CAO and its director Densen Cao abandoned this patent in early 2008
and waited more than five months before claiming the abandonment was
'unintentional,' in an effort to revive it.
"CAO's diode is an inferior product manufactured in China," added
Pignatelli. "It is costly, has less laser power and fewer features
when compared to ezlase, and it also has a large physical footprint
and unpleasant design. We believe CAO, who clearly cannot fairly
compete with BIOLASE among the dental community, has instead turned
to the court system with this lawsuit, which we strongly believe to
be frivolous, in an attempt to exploit us and to try and achieve what
it clearly cannot accomplish in the marketplace.
"We look forward to our day in court," continued Pignatelli, "and we
are carefully exploring all options available to us, as our IP
portfolio is quite comprehensive."
About BIOLASE Technology, Inc.
BIOLASE Technology, Inc., the World's
leading Dental Laser Company, is a medical technology company that
develops, manufactures and markets dental lasers and also distributes
and markets dental imaging equipment, products that are focused on
technologies that advance the practice of dentistry and medicine. The
Company's laser products incorporate approximately 285 patented and
patent pending technologies designed to provide clinically superior
performance with less pain and faster recovery times. Its imaging
products provide cutting-edge technology at competitive prices to
deliver the best results for dentists and patients. BIOLASE's
principal products are dental laser systems that perform a broad
range of dental procedures, including cosmetic and complex surgical
applications, and a full line of dental imaging equipment. BIOLASE
has sold more than 19,000 lasers among 16,000 customers. Other
products under development address ophthalmology and other medical
and consumer markets.
Comments